Product nameAnti-Bcl-2 (phospho S87) antibody
See all Bcl-2 primary antibodies
DescriptionRabbit polyclonal to Bcl-2 (phospho S87)
Specificityab73985 detects endogenous levels of Bcl-2 only when phosphorylated at serine 87 (Human: Ser87; Mouse: Ser84; Rat: Ser84).
Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
Species reactivityReacts with: Rat, Human
Predicted to work with: Mouse
Synthetic peptide corresponding to Human Bcl-2.
Database link: P10415
- Human thyroid gland tissue. Extracts from HeLa cells, treated with nocodazole (1ug/ml, 18hours).
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Without Mg2+ and Ca2+
Concentration information loading...
PurityProtein A purified
Purification notesab73985 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Our Abpromise guarantee covers the use of ab73985 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 28 kDa (predicted molecular weight: 26 kDa).|
|IHC-P||1/50 - 1/100.|
FunctionSuppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).
Tissue specificityExpressed in a variety of tissues.
Involvement in diseaseA chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
Sequence similaritiesBelongs to the Bcl-2 family.
DomainBH1 and BH2 domains are required for the interaction with BAX and for anti-apoptotic activity.
The BH4 motif is required for anti-apoptotic activity and for interaction with RAF1 and EGLN3.
The loop between motifs BH4 and BH3 is required for the interaction with NLRP1.
modificationsPhosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the anti-apoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Phosphorylated by MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulates starvation-induced autophagy. Dephosphorylated by protein phosphatase 2A (PP2A).
Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity.
Monoubiquitinated by PARK2, leading to increase its stability. Ubiquitinated by SCF(FBXO10), leading to its degradation by the proteasome.
Cellular localizationMitochondrion outer membrane. Nucleus membrane. Endoplasmic reticulum membrane.
- Information by UniProt
- Apoptosis regulator Bcl 2 antibody
- Apoptosis regulator Bcl-2 antibody
- Apoptosis regulator Bcl2 antibody
All lanes : Anti-Bcl-2 (phospho S87) antibody (ab73985) at 1/500 dilution
Lane 1 : Extracts from HeLa cells, treated
with nocodazole (1ug/ml, 18hours)
Lane 2 : Extracts from HeLa cells, treated
with nocodazole (1ug/ml, 18hours) with immunising phosphopeptide at 5 µg
Lysates/proteins at 5 µg per lane.
Predicted band size: 26 kDa
Observed band size: 28 kDa why is the actual band size different from the predicted?
Immunohistochemistry analysis of paraffin-embedded human thyroid gland tissue using ab73985 at 1/50 dilution in the presence (right panel) or absence (left panel) of immunising phosphopeptide.
This product has been referenced in:
- Ayatollahi SA et al. BCL-2 and Bax Expression in Skin Flaps Treated with Finasteride or Azelaic Acid. Iran J Pharm Res 11:1285-90 (2012). Read more (PubMed: 24250563) »
- Teng BT et al. Protective effect of caspase inhibition on compression-induced muscle damage. J Physiol 589:3349-69 (2011). WB ; Rat . Read more (PubMed: 21540338) »